Author

R. J. Buckanovich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. J. Cole· 1 shared A. Yousif· 1 shared D. Chan· 1 shared E. Yoon· 1 shared G. Greg Delgoffe· 1 shared G. Mehta· 1 shared H. U. Osmanbeyoglu· 1 shared I. Chefetz Menaker· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Cole

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivJun 7, 2023

Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer

L. Zhang, S. Cascio, J. W. ellors…·H. U. Osmanbeyoglu

The paper uses single-cell transcriptomics to analyze ovarian cancer microenvironment dynamics, identifying CXCL12-CXCR4 interactions that drive immunosuppression in high-stromal tumors.

DOI 10.1038/s42003-023-05733-x

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivJan 11, 2020

NFATC4 Promotes Quiescence and Chemotherapy Resistance in Ovarian Cancer

A. J. Cole, M. Iyengar, P. OHayer…·R. J. Buckanovich

This study identifies NFATC4 as a regulator of quiescence and chemotherapy resistance in ovarian cancer, showing its role in promoting a non-proliferative state and poor prognosis.

DOI 10.1172/jci.insight.131486

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivSep 16, 2019

The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma

M. Chesnokov, I. Khan, Y. Park…·I. Chefetz Menaker

This study investigates MEK1/2 pathway activity in high-grade serous ovarian carcinoma and shows that its inhibition reduces tumor growth but promotes stem-like properties, suggesting potential resistance mechanisms.

DOI 10.3390/cancers13061369

humanproteomics

𝕏 PostBluesky